A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Part of paid clinical trials in Denver, Colorado.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07146906
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Immunoglobulin A Nephropathy (IgAN)

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • zigakibart — BIOLOGICAL
    zigakibart 600 mg sc injections every second week for 104 weeks (2 years)

Study Details

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Key Dates

Start date
Mar 26, 2026
Status verified
Apr 2026
Primary completion
Jul 12, 2030
Completion
Oct 18, 2030

Study Design

Enrollment
32 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: zigakibart
    zigakibart injections every second week for two years

Primary Outcome Measure

Change in mesangial IgA deposition [ Time Frame: Baseline to Week 53 or 105 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Colorado Kidney Care NephrologyDenverColorado80230
Leigh Collins
[email protected]
Laura Kooienga (PRINCIPAL_INVESTIGATOR)
American Clinical TrialsAcworthGeorgia30101
Chinedu Nweke (PRINCIPAL_INVESTIGATOR)
Inter Med ConsultantsEdinaMinnesota55435
Jonathan Tolins (PRINCIPAL_INVESTIGATOR)

Find similar trials in Denver, CO

By research site
Colorado Kidney Care Nephrology· Denver, COAmerican Clinical Trials· Acworth, GAInter Med Consultants· Edina, MN

Related Studies